# Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

> **NCT05571111** · PHASE2 · WITHDRAWN · sponsor: **Ferring Pharmaceuticals**

## Conditions studied

- Infertility

## Interventions

- **DRUG:** FE 999302
- **DRUG:** Ovitrelle
- **DRUG:** Novarel

## Key facts

- **NCT ID:** NCT05571111
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-04
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-06-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Based on company decision to close the project. No trial participants received any study drug.
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05571111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05571111, "Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05571111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*